{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:15:56Z","timestamp":1793718956480,"version":"4.6.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["Grant No. ZR2021MH039"],"award-info":[{"award-number":["Grant No. ZR2021MH039"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["Grant No. 8217021865"],"award-info":[{"award-number":["Grant No. 8217021865"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Science and Technology Innovation Program","award":["Grant No.202019089"],"award-info":[{"award-number":["Grant No.202019089"]}]},{"name":"Major Project of Shandong University","award":["Grant No. qlyxjy-201830"],"award-info":[{"award-number":["Grant No. qlyxjy-201830"]}]},{"name":"Project of Shandong Provincial Medical Association","award":["Grant No. YXH2024YS039"],"award-info":[{"award-number":["Grant No. YXH2024YS039"]}]},{"name":"Research Fund of Qianfoshan Hospital","award":["Grant No. QYPY2021NSFC0619"],"award-info":[{"award-number":["Grant No. QYPY2021NSFC0619"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10557-025-07670-9","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:59:09Z","timestamp":1737341949000},"page":"287-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3334-4690","authenticated-orcid":false,"given":"Xinyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-710X","authenticated-orcid":false,"given":"Chao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4340-1826","authenticated-orcid":false,"given":"Xiuqing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"7670_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2021.09.001","volume":"335","author":"PA Senior","year":"2021","unstructured":"Senior PA. Glucose as a modifiable cause of atherosclerotic cardiovascular disease: insights from type 1 diabetes and transplantation. Atherosclerosis. 2021;335:16\u201322. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.001.","journal-title":"Atherosclerosis"},{"issue":"4","key":"7670_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660\u201371. https:\/\/doi.org\/10.1007\/s00125-014-3171-6.","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"7670_CR3","doi-asserted-by":"publisher","first-page":"S380","DOI":"10.1007\/s00592-003-0124-9","volume":"40","author":"C Yosefy","year":"2003","unstructured":"Yosefy C. Hyperglycaemia and its relation to cardiovascular morbidity and mortality: has it been resolved? Acta Diabetol. 2003;40(Suppl 2):S380\u20138. https:\/\/doi.org\/10.1007\/s00592-003-0124-9.","journal-title":"Acta Diabetol"},{"key":"7670_CR4","doi-asserted-by":"publisher","first-page":"851941","DOI":"10.3389\/fendo.2022.851941","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Li Y, Li S, Lv J. Endothelial dysfunction and diabetic cardiomyopathy. Front Endocrinol. 2022;13:851941. https:\/\/doi.org\/10.3389\/fendo.2022.851941.","journal-title":"Front Endocrinol"},{"issue":"3","key":"7670_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.diabet.2018.07.003","volume":"45","author":"M Joubert","year":"2019","unstructured":"Joubert M, Manrique A, Cariou B, Prieur X. Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways. Diabetes Metab. 2019;45(3):238\u201347. https:\/\/doi.org\/10.1016\/j.diabet.2018.07.003.","journal-title":"Diabetes Metab"},{"key":"7670_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3389\/fphar.2020.00805","volume":"11","author":"N Nuamnaichati","year":"2020","unstructured":"Nuamnaichati N, Mangmool S, Chattipakorn N, Parichatikanond W. Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac\/PI3K\/Akt pathway. Front Pharmacol. 2020;11:805. https:\/\/doi.org\/10.3389\/fphar.2020.00805.","journal-title":"Front Pharmacol"},{"issue":"4","key":"7670_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/cir.0000000000000366","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, et al. Executive Summary: Heart disease and stroke statistics\u20132016 update: a report from the American Heart Association. Circulation. 2016;133(4):447\u201354. https:\/\/doi.org\/10.1161\/cir.0000000000000366.","journal-title":"Circulation"},{"key":"7670_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Molecular metabolism. 2019;30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010.","journal-title":"Molecular metabolism"},{"key":"7670_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism. 2022;57: 101351. https:\/\/doi.org\/10.1016\/j.molmet.2021.101351.","journal-title":"Molecular metabolism"},{"issue":"13","key":"7670_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMe2401743","volume":"390","author":"DG Standaert","year":"2024","unstructured":"Standaert DG. GLP-1, Parkinson\u2019s disease, and neuroprotection. N Engl J Med. 2024;390(13):1233\u20134. https:\/\/doi.org\/10.1056\/NEJMe2401743.","journal-title":"N Engl J Med"},{"issue":"2","key":"7670_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cmet.2023.01.004","volume":"35","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Coughlan MT, Cooper ME. The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metab. 2023;35(2):253\u201373. https:\/\/doi.org\/10.1016\/j.cmet.2023.01.004.","journal-title":"Cell Metab"},{"issue":"5","key":"7670_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ejim.2014.03.005","volume":"25","author":"A Lund","year":"2014","unstructured":"Lund A, Knop FK, Vilsb\u00f8ll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25(5):407\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2014.03.005.","journal-title":"Eur J Intern Med"},{"issue":"Suppl 1","key":"7670_CR13","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1331\/JAPhA.2009.09078","volume":"49","author":"JJ Neumiller","year":"2009","unstructured":"Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc JAPhA. 2009;49(Suppl 1):S16-29. https:\/\/doi.org\/10.1331\/JAPhA.2009.09078.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"8","key":"7670_CR14","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.3390\/ijms25084407","volume":"25","author":"JE Jalil","year":"2024","unstructured":"Jalil JE, Gabrielli L, Ocaranza MP, et al. New mechanisms to prevent heart failure with preserved ejection fraction using glucagon-like peptide-1 receptor agonism (GLP-1 RA) in metabolic syndrome and in type 2 diabetes: a review. Int J Mol Sci. 2024;25(8):4407. https:\/\/doi.org\/10.3390\/ijms25084407.","journal-title":"Int J Mol Sci"},{"key":"7670_CR15","doi-asserted-by":"publisher","first-page":"721198","DOI":"10.3389\/fendo.2021.721198","volume":"12","author":"QX Li","year":"2021","unstructured":"Li QX, Gao H, Guo YX, et al. GLP-1 and underlying beneficial actions in Alzheimer\u2019s disease, hypertension, and NASH. Front Endocrinol. 2021;12:721198. https:\/\/doi.org\/10.3389\/fendo.2021.721198.","journal-title":"Front Endocrinol"},{"key":"7670_CR16","doi-asserted-by":"publisher","first-page":"101884","DOI":"10.1016\/j.arr.2023.101884","volume":"86","author":"T Yang","year":"2023","unstructured":"Yang T, Zhang D. Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia\/reperfusion injury. Ageing Res Rev. 2023;86:101884. https:\/\/doi.org\/10.1016\/j.arr.2023.101884.","journal-title":"Ageing Res Rev"},{"issue":"11","key":"7670_CR17","doi-asserted-by":"publisher","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","volume":"310","author":"R Wei","year":"2016","unstructured":"Wei R, Ma S, Wang C, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK\/Akt\/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016;310(11):E947\u201357. https:\/\/doi.org\/10.1152\/ajpendo.00400.2015.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"7670_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/dom.14171","volume":"22","author":"GV Graham","year":"2020","unstructured":"Graham GV, McLaughlin CM, Flatt PR. Role of exendin-4 in the Gila monster: further lessons regarding human oral glucagon-like peptide-1 therapy? Diabetes Obes Metab. 2020;22(12):2509\u201311. https:\/\/doi.org\/10.1111\/dom.14171.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"7670_CR19","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13300-021-01113-y","volume":"12","author":"S Kalra","year":"2021","unstructured":"Kalra S, Bhattacharya S, Kapoor N. Contemporary classification of glucagon-like peptide 1 receptor agonists (GLP1RAs). Diabetes. 2021;12(8):2133\u201347. https:\/\/doi.org\/10.1007\/s13300-021-01113-y.","journal-title":"Diabetes"},{"issue":"7","key":"7670_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3810\/pgm.2014.11.2836","volume":"126","author":"MA Young","year":"2014","unstructured":"Young MA, Wald JA, Matthews JE, et al. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014;126(7):84\u201397. https:\/\/doi.org\/10.3810\/pgm.2014.11.2836.","journal-title":"Postgrad Med"},{"issue":"5","key":"7670_CR21","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1021\/acsbiomaterials.3c00137","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yu H, Wang L, et al. Microneedles with two-stage glucose-sensitive controlled release for long-term insulin delivery. ACS Biomater Sci Eng. 2023;9(5):2534\u201344. https:\/\/doi.org\/10.1021\/acsbiomaterials.3c00137.","journal-title":"ACS Biomater Sci Eng"},{"issue":"4","key":"7670_CR22","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.neuroscience.2009.05.025","volume":"162","author":"R Kimura","year":"2009","unstructured":"Kimura R, Okouchi M, Fujioka H, et al. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K\/Akt\/mTOR\/GCLc\/redox signaling pathway. Neuroscience. 2009;162(4):1212\u20139. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.05.025.","journal-title":"Neuroscience"},{"issue":"14","key":"7670_CR23","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1074\/jbc.271.14.8075","volume":"271","author":"B Thorens","year":"1996","unstructured":"Thorens B, D\u00e9riaz N, Bosco D, et al. Protein kinase A-dependent phosphorylation of GLUT2 in pancreatic beta cells. J Biol Chem. 1996;271(14):8075\u201381. https:\/\/doi.org\/10.1074\/jbc.271.14.8075.","journal-title":"J Biol Chem"},{"issue":"8","key":"7670_CR24","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1210\/en.2002-0104","volume":"144","author":"TK Graves","year":"2003","unstructured":"Graves TK, Hinkle PM. Ca(2+)-induced Ca(2+) release in the pancreatic beta-cell: direct evidence of endoplasmic reticulum Ca(2+) release. Endocrinology. 2003;144(8):3565\u201374. https:\/\/doi.org\/10.1210\/en.2002-0104.","journal-title":"Endocrinology"},{"issue":"Pt 1","key":"7670_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1113\/jphysiol.2002.029959","volume":"546","author":"G Kang","year":"2003","unstructured":"Kang G, Holz GG. Amplification of exocytosis by Ca2+-induced Ca2+ release in INS-1 pancreatic beta cells. J Physiol. 2003;546(Pt 1):175\u201389. https:\/\/doi.org\/10.1113\/jphysiol.2002.029959.","journal-title":"J Physiol"},{"issue":"6","key":"7670_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1085\/jgp.200409082","volume":"124","author":"QF Wan","year":"2004","unstructured":"Wan QF, Dong Y, Yang H, et al. Protein kinase activation increases insulin secretion by sensitizing the secretory machinery to Ca2+. J Gen Physiol. 2004;124(6):653\u201362. https:\/\/doi.org\/10.1085\/jgp.200409082.","journal-title":"J Gen Physiol"},{"issue":"8","key":"7670_CR27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00125-003-1159-8","volume":"46","author":"PE MacDonald","year":"2003","unstructured":"MacDonald PE, Wheeler MB. Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets. Diabetologia. 2003;46(8):1046\u201362. https:\/\/doi.org\/10.1007\/s00125-003-1159-8.","journal-title":"Diabetologia"},{"issue":"8","key":"7670_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/dom.12671","volume":"18","author":"A Mari","year":"2016","unstructured":"Mari A, Del Prato S, Ludvik B, et al. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic \u03b2-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(8):834\u20139. https:\/\/doi.org\/10.1111\/dom.12671.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"7670_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","volume":"52","author":"LL Kjems","year":"2003","unstructured":"Kjems LL, Holst JJ, V\u00f8lund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52(2):380\u20136. https:\/\/doi.org\/10.2337\/diabetes.52.2.380.","journal-title":"Diabetes"},{"key":"7670_CR30","doi-asserted-by":"publisher","first-page":"109252","DOI":"10.1016\/j.cbi.2020.109252","volume":"332","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian J, Diao S, et al. GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction. Chem Biol Interact. 2020;332:109252. https:\/\/doi.org\/10.1016\/j.cbi.2020.109252.","journal-title":"Chem Biol Interact"},{"issue":"6","key":"7670_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3390\/ph16060836","volume":"16","author":"S Pandey","year":"2023","unstructured":"Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals. 2023;16(6):836. https:\/\/doi.org\/10.3390\/ph16060836.","journal-title":"Pharmaceuticals"},{"issue":"7","key":"7670_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/1753-0407.12881","volume":"11","author":"DO Son","year":"2019","unstructured":"Son DO, Liu W, Li X, Prud\u2019homme GJ, Wang Q. Combined effect of GABA and glucagon-like peptide-1 receptor agonist on cytokine-induced apoptosis in pancreatic \u03b2-cell line and isolated human islets. J Diabetes. 2019;11(7):563\u201372. https:\/\/doi.org\/10.1111\/1753-0407.12881.","journal-title":"J Diabetes"},{"key":"7670_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-90-481-3271-3_13","volume":"654","author":"B Furman","year":"2010","unstructured":"Furman B, Ong WK, Pyne NJ. Cyclic AMP signaling in pancreatic islets. Adv Exp Med Biol. 2010;654:281\u2013304. https:\/\/doi.org\/10.1007\/978-90-481-3271-3_13.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"7670_CR34","doi-asserted-by":"publisher","first-page":"E1263","DOI":"10.1152\/ajpendo.00600.2012","volume":"304","author":"W Shao","year":"2013","unstructured":"Shao W, Wang Z, Ip W, et al. GLP-1(28\u201336) improves \u03b2-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP\/PKA\/\u03b2-catenin signaling in \u03b2-cells in vitro. Am J Physiol Endocrinol Metab. 2013;304(12):E1263\u201372. https:\/\/doi.org\/10.1152\/ajpendo.00600.2012.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5605","key":"7670_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.1077838","volume":"299","author":"J Rajagopal","year":"2003","unstructured":"Rajagopal J, Anderson WJ, Kume S, Martinez OI, Melton DA. Insulin staining of ES cell progeny from insulin uptake. Science (New York, NY). 2003;299(5605):363. https:\/\/doi.org\/10.1126\/science.1077838.","journal-title":"Science (New York, NY)"},{"issue":"16","key":"7670_CR36","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.Cir.0000127126.73759.23","volume":"109","author":"DJ Lips","year":"2004","unstructured":"Lips DJ, Bueno OF, Wilkins BJ, et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109(16):1938\u201341. https:\/\/doi.org\/10.1161\/01.Cir.0000127126.73759.23.","journal-title":"Circulation"},{"issue":"1","key":"7670_CR37","doi-asserted-by":"publisher","first-page":"9100","DOI":"10.1038\/s41598-017-09898-4","volume":"7","author":"J Fusco","year":"2017","unstructured":"Fusco J, Xiao X, Prasadan K, et al. GLP-1\/exendin-4 induces \u03b2-cell proliferation via the epidermal growth factor receptor. Sci Rep. 2017;7(1):9100. https:\/\/doi.org\/10.1038\/s41598-017-09898-4.","journal-title":"Sci Rep"},{"issue":"3","key":"7670_CR38","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","volume":"113","author":"ME Doyle","year":"2007","unstructured":"Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113(3):546\u201393. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.11.007.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"7670_CR39","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db05-0825","volume":"55","author":"J Buteau","year":"2006","unstructured":"Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes. 2006;55(5):1190\u20136. https:\/\/doi.org\/10.2337\/db05-0825.","journal-title":"Diabetes"},{"issue":"5","key":"7670_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","volume":"432","author":"A Tomas","year":"2020","unstructured":"Tomas A, Jones B, Leech C. New insights into beta-cell GLP-1 receptor and cAMP signaling. J Mol Biol. 2020;432(5):1347\u201366. https:\/\/doi.org\/10.1016\/j.jmb.2019.08.009.","journal-title":"J Mol Biol"},{"issue":"4","key":"7670_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4161\/15384101.2014.991572","volume":"14","author":"M Morita","year":"2015","unstructured":"Morita M, Gravel SP, Hulea L, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell cycle (Georgetown, Tex). 2015;14(4):473\u201380. https:\/\/doi.org\/10.4161\/15384101.2014.991572.","journal-title":"Cell cycle (Georgetown, Tex)"},{"issue":"4","key":"7670_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nm.3820","volume":"21","author":"P Wang","year":"2015","unstructured":"Wang P, Alvarez-Perez JC, Felsenfeld DP, et al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med. 2015;21(4):383\u20138. https:\/\/doi.org\/10.1038\/nm.3820.","journal-title":"Nat Med"},{"key":"7670_CR43","doi-asserted-by":"publisher","unstructured":"Ackeifi C, Swartz E, Kumar K et al. Pharmacologic and genetic approaches define human pancreatic \u03b2 cell mitogenic targets of DYRK1A inhibitors. JCI Insight. 2020;5(1). https:\/\/doi.org\/10.1172\/jci.insight.132594","DOI":"10.1172\/jci.insight.132594"},{"issue":"12","key":"7670_CR44","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1016\/j.xcrm.2024.101832","volume":"5","author":"E Karakose","year":"2024","unstructured":"Karakose E, Wang X, Wang P, et al. Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors. Cell Rep Med. 2024;5(12):101832. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101832.","journal-title":"Cell Rep Med"},{"issue":"3","key":"7670_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s42000-018-0038-0","volume":"17","author":"D Sfairopoulos","year":"2018","unstructured":"Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens). 2018;17(3):333\u201350. https:\/\/doi.org\/10.1007\/s42000-018-0038-0.","journal-title":"Hormones (Athens)"},{"issue":"2","key":"7670_CR46","doi-asserted-by":"publisher","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","volume":"318","author":"AVR Hviid","year":"2020","unstructured":"Hviid AVR, S\u00f8rensen CM. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. Am J Physiol Renal Physiol. 2020;318(2):F443\u201354. https:\/\/doi.org\/10.1152\/ajprenal.00280.2019.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"7670_CR47","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1006\/jmcc.2002.2014","volume":"34","author":"DM Valks","year":"2002","unstructured":"Valks DM, Cook SA, Pham FH, et al. Phenylephrine promotes phosphorylation of Bad in cardiac myocytes through the extracellular signal-regulated kinases 1\/2 and protein kinase A. J Mol Cell Cardiol. 2002;34(7):749\u201363. https:\/\/doi.org\/10.1006\/jmcc.2002.2014.","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"7670_CR48","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00125-017-4315-2","volume":"60","author":"A \u00d8rgaard","year":"2017","unstructured":"\u00d8rgaard A, Holst JJ. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia. 2017;60(9):1731\u20139. https:\/\/doi.org\/10.1007\/s00125-017-4315-2.","journal-title":"Diabetologia"},{"issue":"1\u20133","key":"7670_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0014-2999(03)01692-3","volume":"469","author":"RA Silvestre","year":"2003","unstructured":"Silvestre RA, Rodr\u00edguez-Gallardo J, Egido EM, Marco J. Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol. 2003;469(1\u20133):195\u2013200. https:\/\/doi.org\/10.1016\/s0014-2999(03)01692-3.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"7670_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/modpathol.2014.113","volume":"28","author":"B Waser","year":"2015","unstructured":"Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Modern Pathol. 2015;28(3):391\u2013402. https:\/\/doi.org\/10.1038\/modpathol.2014.113.","journal-title":"Modern Pathol"},{"issue":"12","key":"7670_CR51","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","volume":"51","author":"J de Heer","year":"2008","unstructured":"de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51(12):2263\u201370. https:\/\/doi.org\/10.1007\/s00125-008-1149-y.","journal-title":"Diabetologia"},{"issue":"17","key":"7670_CR52","doi-asserted-by":"publisher","first-page":"e13852","DOI":"10.14814\/phy2.13852","volume":"6","author":"R Ramracheya","year":"2018","unstructured":"Ramracheya R, Chapman C, Chibalina M, et al. GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca(2+) channels. Physiol Rep. 2018;6(17):e13852. https:\/\/doi.org\/10.14814\/phy2.13852.","journal-title":"Physiol Rep"},{"issue":"19","key":"7670_CR53","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1161\/circulationaha.117.030486","volume":"137","author":"X Zhang","year":"2018","unstructured":"Zhang X, Ji R, Liao X, et al. MicroRNA-195 regulates metabolism in failing myocardium via alterations in sirtuin 3 expression and mitochondrial protein acetylation. Circulation. 2018;137(19):2052\u201367. https:\/\/doi.org\/10.1161\/circulationaha.117.030486.","journal-title":"Circulation"},{"issue":"4","key":"7670_CR54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1161\/circheartfailure.114.000346","volume":"7","author":"KB Margulies","year":"2014","unstructured":"Margulies KB, Anstrom KJ, Hernandez AF, et al. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail. 2014;7(4):673\u20139. https:\/\/doi.org\/10.1161\/circheartfailure.114.000346.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"7670_CR55","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1161\/01.Cir.0000139339.85840.Dd","volume":"110","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955\u201361. https:\/\/doi.org\/10.1161\/01.Cir.0000139339.85840.Dd.","journal-title":"Circulation"},{"issue":"6","key":"7670_CR56","doi-asserted-by":"publisher","first-page":"H2401","DOI":"10.1152\/ajpheart.00347.2005","volume":"289","author":"LA Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289(6):H2401\u20138. https:\/\/doi.org\/10.1152\/ajpheart.00347.2005.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"7670_CR57","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.Cir.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962\u20135. https:\/\/doi.org\/10.1161\/01.Cir.0000120505.91348.58.","journal-title":"Circulation"},{"issue":"9","key":"7670_CR58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"GG Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2006.08.211.","journal-title":"J Card Fail"},{"key":"7670_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12933-014-0115-x","volume":"13","author":"M Chen","year":"2014","unstructured":"Chen M, Angeli FS, Shen YT, Shannon RP. GLP-1 (7\u201336) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles. Cardiovasc Diabetol. 2014;13:115. https:\/\/doi.org\/10.1186\/s12933-014-0115-x.","journal-title":"Cardiovasc Diabetol"},{"key":"7670_CR60","doi-asserted-by":"publisher","first-page":"709703","DOI":"10.3389\/fphys.2021.709703","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu J, Dong E, Zhang Y, Xiao H. The role of the inflammasome in heart failure. Front Physiol. 2021;12:709703. https:\/\/doi.org\/10.3389\/fphys.2021.709703.","journal-title":"Front Physiol"},{"issue":"9","key":"7670_CR61","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/iub.2046","volume":"71","author":"W Yue","year":"2019","unstructured":"Yue W, Li Y, Ou D, Yang Q. The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. 2019;71(9):1347\u201354. https:\/\/doi.org\/10.1002\/iub.2046.","journal-title":"IUBMB Life"},{"issue":"4","key":"7670_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1210\/me.2014-1346","volume":"29","author":"S Mangmool","year":"2015","unstructured":"Mangmool S, Hemplueksa P, Parichatikanond W, Chattipakorn N. Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes. Mol Endocrinol. 2015;29(4):583\u201396. https:\/\/doi.org\/10.1210\/me.2014-1346.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"7670_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-020-07088-5","volume":"35","author":"XJ Bai","year":"2021","unstructured":"Bai XJ, Hao JT, Zheng RH, et al. Glucagon-like peptide-1 analog liraglutide attenuates pressure-overload induced cardiac hypertrophy and apoptosis through activating ATP sensitive potassium channels. Cardiovasc Drugs Ther. 2021;35(1):87\u2013101. https:\/\/doi.org\/10.1007\/s10557-020-07088-5.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7670_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.peptides.2017.02.008","volume":"90","author":"J Chen","year":"2017","unstructured":"Chen J, Wang D, Wang F, et al. Exendin-4 inhibits structural remodeling and improves Ca(2+) homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS\/cGMP\/PKG pathway. Peptides. 2017;90:69\u201377. https:\/\/doi.org\/10.1016\/j.peptides.2017.02.008.","journal-title":"Peptides"},{"issue":"1","key":"7670_CR65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgad398","volume":"109","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Sharma A, Butler J, et al. Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. J Clin Endocrinol Metab. 2023;109(1):4\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgad398.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7670_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"7670_CR67","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"key":"7670_CR68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2024","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"7670_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03374-z","author":"BA Borlaug","year":"2024","unstructured":"Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03374-z.","journal-title":"Nat Med"},{"key":"7670_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.001","author":"CM Kramer","year":"2024","unstructured":"Kramer CM, Borlaug BA, Zile MM, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.001.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7670_CR71","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ejhf.707","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M. Liraglutide in heart failure: caution is needed. Eur J Heart Fail. 2017;19(1):78\u20139. https:\/\/doi.org\/10.1002\/ejhf.707.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"7670_CR72","doi-asserted-by":"publisher","first-page":"2320401","DOI":"10.1080\/08037051.2024.2320401","volume":"33","author":"J Redon","year":"2024","unstructured":"Redon J, Carmena R. Present and future of drug therapy in hypertension: an overview. Blood Press. 2024;33(1):2320401. https:\/\/doi.org\/10.1080\/08037051.2024.2320401.","journal-title":"Blood Press"},{"issue":"6","key":"7670_CR73","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","volume":"21","author":"M Yu","year":"2003","unstructured":"Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21(6):1125\u201335. https:\/\/doi.org\/10.1097\/00004872-200306000-00012.","journal-title":"J Hypertens"},{"issue":"5","key":"7670_CR74","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/circresaha.121.319874","volume":"130","author":"AG Pauza","year":"2022","unstructured":"Pauza AG, Thakkar P, Tasic T, et al. GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res. 2022;130(5):694\u2013707. https:\/\/doi.org\/10.1161\/circresaha.121.319874.","journal-title":"Circ Res"},{"issue":"1","key":"7670_CR75","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K, et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145\u201358. https:\/\/doi.org\/10.1161\/atv.0000615456.97862.30.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1\u20132","key":"7670_CR76","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.bbrc.2015.09.179","volume":"468","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, He X, Chen Y, et al. Exendin-4 attenuates cardiac hypertrophy via AMPK\/mTOR signaling pathway activation. Biochem Biophys Res Commun. 2015;468(1\u20132):394\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2015.09.179.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"7670_CR77","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/hypertensionaha.120.14868","volume":"76","author":"FL Martins","year":"2020","unstructured":"Martins FL, Bailey MA, Girardi ACC. Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na(+)\/H(+) exchanger isoform 3, renal angiotensin II, and insulin sensitivity. Hypertension. 2020;76(3):839\u201348. https:\/\/doi.org\/10.1161\/hypertensionaha.120.14868.","journal-title":"Hypertension"},{"issue":"1","key":"7670_CR78","doi-asserted-by":"publisher","first-page":"12986","DOI":"10.1038\/s41598-019-49364-x","volume":"9","author":"K Katsurada","year":"2019","unstructured":"Katsurada K, Nakata M, Saito T, et al. Central glucagon-like peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats. Sci Rep. 2019;9(1):12986. https:\/\/doi.org\/10.1038\/s41598-019-49364-x.","journal-title":"Sci Rep"},{"key":"7670_CR79","doi-asserted-by":"publisher","first-page":"i4098","DOI":"10.1136\/bmj.i4098","volume":"354","author":"SL Stevens","year":"2016","unstructured":"Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ (Clinical research ed). 2016;354:i4098. https:\/\/doi.org\/10.1136\/bmj.i4098.","journal-title":"BMJ (Clinical research ed)"},{"issue":"5","key":"7670_CR80","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1159\/000527675","volume":"69","author":"Y Xu","year":"2023","unstructured":"Xu Y, Chen C, Yang Y, et al. Activation of the vascular smooth muscle GLP-1\/NCX1 pathway regulates cytoplasmic Ca2+ homeostasis and improves blood pressure variability in hypertension. Gerontology. 2023;69(5):603\u201314. https:\/\/doi.org\/10.1159\/000527675.","journal-title":"Gerontology"},{"key":"7670_CR81","doi-asserted-by":"publisher","first-page":"31788","DOI":"10.1038\/srep31788","volume":"6","author":"MY Lee","year":"2016","unstructured":"Lee MY, Tsai KB, Hsu JH, et al. Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS\/sGC\/PKG pathways. Sci Rep. 2016;6:31788. https:\/\/doi.org\/10.1038\/srep31788.","journal-title":"Sci Rep"},{"issue":"4","key":"7670_CR82","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jtcvs.2017.10.085","volume":"155","author":"JN Roan","year":"2018","unstructured":"Roan JN, Hsu CH, Fang SY, et al. Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension. J Thorac Cardiovasc Surg. 2018;155(4):1661-9.e4. https:\/\/doi.org\/10.1016\/j.jtcvs.2017.10.085.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"7670_CR83","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00125-006-0297-1","volume":"49","author":"IM Stratton","year":"2006","unstructured":"Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761\u20139. https:\/\/doi.org\/10.1007\/s00125-006-0297-1.","journal-title":"Diabetologia"},{"key":"7670_CR84","doi-asserted-by":"publisher","first-page":"4020492","DOI":"10.1155\/2018\/4020492","volume":"2018","author":"MI Del Olmo-Garcia","year":"2018","unstructured":"Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:4020492. https:\/\/doi.org\/10.1155\/2018\/4020492.","journal-title":"J Diabetes Res"},{"issue":"3","key":"7670_CR85","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/dom.13541","volume":"21","author":"A Liakos","year":"2019","unstructured":"Liakos A, Lambadiari V, Bargiota A, et al. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2019;21(3):517\u201324. https:\/\/doi.org\/10.1111\/dom.13541.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"7670_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337. https:\/\/doi.org\/10.1016\/j.diabres.2015.07.015.","journal-title":"Diabetes Res Clin Pract"},{"key":"7670_CR87","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2840-9-6","volume":"9","author":"A Gill","year":"2010","unstructured":"Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6. https:\/\/doi.org\/10.1186\/1475-2840-9-6.","journal-title":"Cardiovasc Diabetol"},{"key":"7670_CR88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.diabres.2019.05.001","volume":"153","author":"MHA Muskiet","year":"2019","unstructured":"Muskiet MHA, Bunck MC, Heine RJ, et al. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial. Diabetes Res Clin Pract. 2019;153:14\u201322. https:\/\/doi.org\/10.1016\/j.diabres.2019.05.001.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"7670_CR89","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jash.2018.02.003","volume":"12","author":"J Jendle","year":"2018","unstructured":"Jendle J, Fang X, Cao Y, et al. Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study. J Am Soc Hypertension. 2018;12(5):346\u201355. https:\/\/doi.org\/10.1016\/j.jash.2018.02.003.","journal-title":"J Am Soc Hypertension"},{"issue":"6","key":"7670_CR90","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/dom.15529","volume":"26","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Lumbang GNO, Gaid DRM, et al. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression. Diabetes Obes Metab. 2024;26(6):2209\u201328. https:\/\/doi.org\/10.1111\/dom.15529.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"7670_CR91","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000518325","volume":"14","author":"CL Haase","year":"2021","unstructured":"Haase CL, Serratore Achenbach MG, Lucrezi G, et al. Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland. Obesity Facts. 2021;14(5):568\u201376. https:\/\/doi.org\/10.1159\/000518325.","journal-title":"Obesity Facts"},{"issue":"4","key":"7670_CR92","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12265-020-09984-5","volume":"14","author":"RA Eid","year":"2021","unstructured":"Eid RA, Bin-Meferij MM, El-Kott AF, et al. Exendin-4 protects against myocardial ischemia-reperfusion injury by upregulation of SIRT1 and SIRT3 and activation of AMPK. J Cardiovasc Transl Res. 2021;14(4):619\u201335. https:\/\/doi.org\/10.1007\/s12265-020-09984-5.","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"7670_CR93","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3892\/ijmm.2017.3318","volume":"41","author":"G Chang","year":"2018","unstructured":"Chang G, Liu J, Qin S, et al. Cardioprotection by exenatide: a novel mechanism via improving mitochondrial function involving the GLP-1 receptor\/cAMP\/PKA pathway. Int J Mol Med. 2018;41(3):1693\u2013703. https:\/\/doi.org\/10.3892\/ijmm.2017.3318.","journal-title":"Int J Mol Med"},{"issue":"4","key":"7670_CR94","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/1535370214522177","volume":"239","author":"G Chang","year":"2014","unstructured":"Chang G, Zhang D, Liu J, et al. Exenatide protects against hypoxia\/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells. Exp Biol Med (Maywood). 2014;239(4):414\u201322. https:\/\/doi.org\/10.1177\/1535370214522177.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"7670_CR95","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbrc.2018.03.142","volume":"499","author":"A Chen","year":"2018","unstructured":"Chen A, Chen Z, Xia Y, et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1\/NOX4\/ROS pathway in H9c2 cells. Biochem Biophys Res Commun. 2018;499(2):267\u201372. https:\/\/doi.org\/10.1016\/j.bbrc.2018.03.142.","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"7670_CR96","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2174\/1389450117666160401120308","volume":"18","author":"HJ Chi","year":"2017","unstructured":"Chi HJ, Chen ML, Yang XC, et al. Progress in therapies for myocardial ischemia reperfusion injury. Curr Drug Targets. 2017;18(15):1712\u201321. https:\/\/doi.org\/10.2174\/1389450117666160401120308.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"7670_CR97","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.104.073890","volume":"312","author":"LA Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Doverspike A, Hentosz T, et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005;312(1):303\u20138. https:\/\/doi.org\/10.1124\/jpet.104.073890.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"7670_CR98","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","volume":"53","author":"L Timmers","year":"2009","unstructured":"Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53(6):501\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.033.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"7670_CR99","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, Vejlstrup N, Kelb\u00e6k H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehr309.","journal-title":"Eur Heart J"},{"issue":"2","key":"7670_CR100","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/circinterventions.112.968388","volume":"5","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, Kelb\u00e6k H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5(2):288\u201395. https:\/\/doi.org\/10.1161\/circinterventions.112.968388.","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"7670_CR101","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijcard.2012.09.204","volume":"167","author":"FJ Bernink","year":"2013","unstructured":"Bernink FJ, Timmers L, Diamant M, et al. Effect of additional treatment with EXenatide in patients with an acute myocardial infarction: the EXAMI study. Int J Cardiol. 2013;167(1):289\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2012.09.204.","journal-title":"Int J Cardiol"},{"issue":"1","key":"7670_CR102","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10020-024-00817-8","volume":"30","author":"K Chen","year":"2024","unstructured":"Chen K, Jin HJ, Wu ZH, et al. Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway. Molecular medicine (Cambridge, Mass). 2024;30(1):58. https:\/\/doi.org\/10.1186\/s10020-024-00817-8.","journal-title":"Molecular medicine (Cambridge, Mass)"},{"key":"7670_CR103","doi-asserted-by":"publisher","first-page":"5013622","DOI":"10.1155\/2022\/5013622","volume":"2022","author":"LL Shi","year":"2022","unstructured":"Shi LL, Hao M, Jin ZY, et al. Liraglutide alleviates diabetic atherosclerosis through regulating calcification of vascular smooth muscle cells. Dis Markers. 2022;2022:5013622. https:\/\/doi.org\/10.1155\/2022\/5013622.","journal-title":"Dis Markers"},{"issue":"1","key":"7670_CR104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12020-015-0852-y","volume":"53","author":"ST Tang","year":"2016","unstructured":"Tang ST, Zhang Q, Tang HQ, et al. Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor \u03baB signaling pathways. Endocrine. 2016;53(1):107\u201316. https:\/\/doi.org\/10.1007\/s12020-015-0852-y.","journal-title":"Endocrine"},{"issue":"9","key":"7670_CR105","doi-asserted-by":"publisher","first-page":"8640","DOI":"10.18632\/aging.103181","volume":"12","author":"Z Fu","year":"2020","unstructured":"Fu Z, Mui D, Zhu H, Zhang Y. Exenatide inhibits NF-\u03baB and attenuates ER stress in diabetic cardiomyocyte models. Aging. 2020;12(9):8640\u201351. https:\/\/doi.org\/10.18632\/aging.103181.","journal-title":"Aging"},{"issue":"4","key":"7670_CR106","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2337\/db14-1149","volume":"64","author":"ML Balestrieri","year":"2015","unstructured":"Balestrieri ML, Rizzo MR, Barbieri M, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2015;64(4):1395\u2013406. https:\/\/doi.org\/10.2337\/db14-1149.","journal-title":"Diabetes"},{"issue":"1","key":"7670_CR107","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12933-020-01014-7","volume":"19","author":"J Zhang","year":"2020","unstructured":"Zhang J, Xian TZ, Wu MX, et al. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial. Cardiovasc Diabetol. 2020;19(1):48. https:\/\/doi.org\/10.1186\/s12933-020-01014-7.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07670-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:58:44Z","timestamp":1770202724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7670"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07670-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"30 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}